Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks

NCT05626634 is registered in ClinicalTrials.gov with Longboard Pharmaceuticals as lead sponsor.

NCT NCT05626634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05626634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks
Lead sponsor
Longboard Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2022
Completion date
December 20, 2024
Enrollment
41 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

developmental and epileptic encephalopathy, dravet syndrome, lennox-gastaut syndrome